NT5E and colorectal carcinoma: For instance, the NCT02503774 phase I trial of anti-CD73 with or without anti-PD-L1 enrolled 77 patients with CRC, 73 with pancreatic adenocarcinoma (PDAC) and 42 with NSCLC positive for EGFR mutation (EGFRm).